Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

New England Journal of Medicine

Volumn 339, Issue 19, 1998, Pages 1341-1348

  Soignet, Steven L ^a   Maslak, Peter ^a   Wang, Zhu Gang ^a   Jhanwar, Suresh ^a   Calleja, Elizabeth ^a   Dardashti, Laura J ^a   Corso, Diane ^a   DeBlasio, Anthony ^a   Gabrilove, Janice ^a   Scheinberg, David A ^a   Pandolfi, Pier Paolo ^a   Warrell Jr , Raymond P ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CD11B ANTIGEN; CD33 ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RASH; REMISSION; TREATMENT OUTCOME; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BONE MARROW CELLS; CASPASES; CELL DIFFERENTIATION; CHILD; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; RECURRENCE; REMISSION INDUCTION;

EID: 0032487923     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199811053391901     Document Type: Article

References (43)

1. Warrell RP Jr, de Thé H, Wang Z-Y, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-89.
2. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:558-61.
3. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249:1577-80.
4. Soignet S, Fleischauer A, Polyak T, Heller G, Warrell RP Jr. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother Pharmacol 1997;40:Suppl:S25-S29.
5. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993;82:3241-9.
6. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-53.
7. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-21.
8. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8. [Erratum, N Engl J Med 1997;337:1639.]
9. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
10. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
11. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-93.
12. Sun HD, Ma L, Hu XC, Zhang TD. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992; 12:170-1.
13. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;17:58-62.
14. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
15. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996;88:1052-61.
16. König A, Wrazel L, Warrell RP Jr, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90:562-70.
17. Zhu J, Koken MHM, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:3978-83.
18. Shao W, Fanelli M, Ferrara FF, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998;90:124-33.
19. Miller WH Jr, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992;89:2694-8.
20. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 1993;82:1689-94.
21. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-6.
22. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994;84:3843-9.
23. Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437-8.
24. Biondi A, Rambaldi A, Pandolfi PP, et al. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992;80:492-7.
25. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse transcriptase PCR: evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 1998;10: 61-6.
26. RT-PCR in acute promyelocytic leukemia: second workshop of the European Retinoic Group, Paris, France, 17-18 December 1994. Leukemia 1996;10:368-71.
27. Westervelt P, Pollock J, Haug J, Ley TJ, DiPersio JF. Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia. Blood 1997;90:Suppl 1:249b. abstract.
28. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994;76:333-43.
29. Wang Z-G, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML/RAR-α independent manner. Blood 1998;92:1497-504.
30. Calleja EM, Gabrilove JL, Warrell RP Jr. Arsenic trioxide inhibits cell survival in a variety of cancer cell types. Proc Am Soc Clin Oncol 1998;17: 218a. abstract.
31. Yang CH, Wang TY, Chen YC. Cytotoxicity of arsenic trioxide in cancer cell lines. Proc Am Assoc Cancer Res 1998;39:227. abstract.
32. Bainbridge WS. The cancer problem. New York: Macmillan, 1914: 271-6.
33. Forkner CE, Scott TFM. Arsenic as therapeutic agent in chronic myelogenous leukemia: preliminary report. JAMA 1931;97:3-5.
34. Burri C, Blatz T, Giroud C, Doua F, Welker HA, Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 1993;39:225-34.
35. Terstappen LWMM, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol 1990;48:138-48.
36. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993;75:641-52.
37. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326:1-16.
38. Thornberry NA. The caspase family of cysteine proteases. Br Med Bull 1997;53:478-90.
39. Martins LM, Mesner PW, Kottke TJ, et al. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood 1997;90:4283-96.
40. Watson RWG, Rotstein OD, Parodo J, Bitar R, Hackam D, Marshall JC. Granulocytic differentiation of HL-60 cells results in spontaneous apoptosis mediated by increased caspase expression. FEBS Lett 1997;412: 603-9.
41. Piedrafita FJ, Pfahl M. Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 1997;17:6348-58.
42. Carter NS, Fairlamb AH. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 1993;361:173-6. [Erratum, Nature 1993;361:374.]
43. Wang Z, Dey S, Rosen BP, Rossman TG. Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol Appl Pharmacol 1996;137:112-9.